Lucidi Valerio, Gustot Thierry, Moreno Christophe, Donckier Vincent
aLiver Transplant Unit, Department of Abdominal Surgery, Université Libre de Bruxelles (ULB) bLiver Transplant Unit, Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, Hôpital Erasme, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Curr Opin Crit Care. 2015 Apr;21(2):163-70. doi: 10.1097/MCC.0000000000000186.
The scarcity of liver grafts requires to optimize the results of transplantation. Extensions and alternatives of liver transplantation have to be regularly evaluated.
Acute-on-chronic liver failure and severe alcoholic hepatitis may represent potential extensions of transplant indications. In these diseases, selected patients could obtain a significant benefit from liver transplantation, whereas long-term outcomes and global impact on waiting lists remain to be evaluated prospectively. Alternatives to transplantation may be represented by recent progress in the management of hepatitis C and the treatment of hepatocellular carcinoma. In hepatitis C, new drug combinations may improve the disease control, reducing the progression to cirrhosis and also the risk of post-transplant reinfection allowing to anticipate a future decrease in the indications for transplantation and retransplantation in these patients. In hepatocellular carcinoma, thanks to improvements in operative techniques and better identification of prognostic factors of cancer recurrency, surgical resection or radiofrequency destruction could appear now as true alternatives to transplant in highly selected patients.
Before implementation of these potential changes into decisional algorithms for listing and organ allocation, their consequences, either for patient's individual benefit or for global transplant outcomes, should be closely evaluated using objective long-term end points and taking into account the ethical recommendations for organ transplantation.
肝移植供体稀缺,需要优化移植效果。必须定期评估肝移植的扩展方式和替代方案。
慢加急性肝衰竭和严重酒精性肝炎可能是移植适应证的潜在扩展情况。在这些疾病中,部分患者可能从肝移植中显著获益,但其长期预后以及对等待名单的整体影响仍有待前瞻性评估。移植替代方案可能体现在丙型肝炎管理和肝细胞癌治疗的最新进展中。在丙型肝炎方面,新的药物组合可能改善疾病控制,减少肝硬化进展以及移植后再感染风险,从而有望在未来减少这些患者的移植和再次移植适应证。在肝细胞癌方面,由于手术技术的改进以及对癌症复发预后因素的更好识别,对于经过严格筛选的患者,手术切除或射频消融目前可能成为真正的移植替代方案。
在将这些潜在变化纳入 listing 和器官分配的决策算法之前,应使用客观的长期终点,并考虑器官移植的伦理建议,密切评估其对患者个体获益或整体移植结果的影响。